Alois Alzheimer

A Mais Completa Biografia Ilustrada de Alois Alzheimer

O Portal de Conteúdo Sobre Alzheimer na Web Mundial

Novas Drogas - Perspectivas (Parte 3)

Pesquisa mundial e Alzheimer
No mundo, 546 laboratórios da indústria farmacêutica e de biotecnologia estão envolvidos em novas descobertas, desenvolvendo e estudando novas drogas para o tratamento e prevenção da doença de Alzheimer.
Desse total, 114 estão em desenvolvimento de estudos clínicos:

Absorption Systems: www.absorption.com
Acadia Pharmaceuticals: www.acadia-pharm.com
Acumen Pharmaceuticals: www.acumenpharm.com
Advanced Cell and Gene Therapy: www.ac-gt.com
Advanced Life Sciences:www.advancedlifesciences.com
Albany Molecular Research: www.albmolecular.com
Althea Technologies: www.altheatech.com
Alza Corporation: www.alza.com
American Home Products: www.wyeth.com
Anabase International Corp: www.anabase.com
AnaSpec: www.anaspec.co
Aptuit: www.aptuit.com
Arkios BioDevelopment International: www.arkios.com
Array Biopharma: www.arraybiopharma.com
Ashvins Group: www.ashvinsgroup.com
Aspire IRB: www.aspire-irb.com
Assay Designs: www.assaydesigns.com
Asterand: www.asterand.com
Aventis Pharmaceuticals (antiga Hoechst): www.aventis.com
Axonyx: www.axonyx.com
Baxter Healthcare: www.baxter.com
BioArctic Neuroscience AB: www.bioarctic.se
Biological Test Center (BTC): www.biologicaltestcenter.com
Bionomics Limited: www.bionomics.com.au
Bio-Rad Laboratories: www.bio-rad.com
BioReliance Corporation: www.bioreliance.com
BioVision: www.biovisio.com
Catalyst Pharma Group: www.catalystpharm.com
Cambrex: www.cambrex.com
Cantest Clinical Research: www.cantestclinical.com
Cato Research: www.cato.com
Ceregene: www.ceregene.com
Charles River Laboratories: www.criver.com
Clinical Network Services Pty: www.clinical. net.au
Clinimetrics Research Associates: www.clinimetrics.com
Cortex Pharmaceuticals: www.cortexpharm.com
Daiichi Pharmaceuticals: www.daiichius.com
DeltaPharma: www.delta-pharma.com
Diosynth Biotechnology (Morrisville): www.diosynthbiotechnology.com
DiscoveRx Corporation: www.discoverx.com
Ebewe Pharmaceutical: www.ebewe.co.at
Elan Pharmaceuticals: www.elan.com
Eli Lilly and Company: www.lilly.com
Epix Pharmaceuticals: www.epixpharma.com
Formatech: www.formatech.com
Fulcrum Pharma Developments: www.fulcrumpharma.com
GlaxoSmithKline: www.gsk.com
i3 Global: www.i3global.com
Icon Clinical Research: www.iconclinical.com
ID Business Solutions (IDBS): www.idbs.com
Immune Network Ltd.: www.immunenetwork.com
INC Research: www.incresearch.com
Intra-Cellular Therapies: www.intracellulartherapies.com
Lab Vision: www.labvision.com
Laureate Pharma: www.laureatepharma.com
Lexicon Pharmaceuticals: www.lexicon-genetics.com
Martek Biosciences Corporation: www.martek.com
Mediolanum Pharmaceuticals: www.mediolanum-farma.com
Medivation: www.medivation.net
Memory Pharmaceuticals Corporation: www.memorypharma.com
Merck & Co.:www.merck.com
MitoKor: www.migenix.com
Mitsubishi Pharma Corporation: www.m-pharma.co.jp
Molecular Medicine BioServices: www.molecularmed.com
MPI Research: www.mpiresearch.com
MWG Biotech: www.mwgbiotech.com
Myriad Pharmaceuticals: www.myriad.com
Nastech Pharmaceutical Company: www.nastech.com
NeoTherapeutics: www.neotherapeutics.com
Neurochem: www.neurochem.com
Neuro-Hitech: http://www.neurohitech.com
Neurolab: www.neurolab.fr
Neurosearch A/S: www.neurosearch.com
NuPharm Laboratories Ltd.: www.nupharmlabs.com
Ockham Development Group: www.ockham.com/ockham
Omnicare Clinical Research: www.omnicarecr.com
Parexel International: www.parexel.com
Pfizer: www.pfizer.com
Pharmaceutical Profiles Group: www.pharmprofiles.com
Pharmacopeia: www.pharmacopeia.com
PharmaCore®: www.pharmacore.com
Pharmagene Laboratories Limited: www.asterand.com/Asterand
PharmaNet: www.pharmanet-cro.com
Pharmidex: www.pharmidex.com
Probiodrug AG: www.probiodrug.de
Proctor & Gamble: www.pgpharma.com
ProTrials Research: www.protrials.com
PsychoGenics: www.psychogenics.com
Qiagen: www.qiagen.com
QSV Biologics Ltd.: www.qsvbiologics.com
Renovis: www.renovis.com
Rho: www.rhoworld.com
Roche Pharmaceuticals: www.roche.com/home.html
Saegis Pharmaceuticals: www.saegispharma.com
Sentrx: www.sentrx.com
Sigma-Tau Pharmaceuticals: www.sigmatau.com
SkeleTech: www.skeletech.com
Southern Research Institute: www.southernresearch.org
Specs: www.specs.net
Supernus Pharmaceuticals: www.supernuspharma.com
SynPep Corporation: www.synpep.com
Synteract: www.synteract.com
Syreon Corporation: www.syreon.com
Takeda Chemical Industries: www.takeda.com
Targacept: www.targacept.com
TransTech Pharma: www.ttpharma.com
Voyager Pharmaceutical Corporation: www.voyagerpharma.com
VWR International: www.vwr.com
Warner-Lambert: www.pfizer.com
Westat: www.westat.com/clinicaltrials
WuXi PharmaTech: www.pharmatechs.com
Wyeth: www.wyeth.com

Referências Bibliográficas
Aisen, PS; Schafer, KA; Grundman, M. - Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
Al-Jafari AA, Kamal MA, Greig NH, Alhomida AS, Perry ER. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine. Biochem Biophys Res Commun. 1998 Jul 9;248(1):180-5.
Alvarez XA, Cacabelos R, Laredo M, Couceiro V, Sampedro C, Varela M, Corzo L, Fernandez-Novoa L, Vargas M, Aleixandre M, Linares C, Granizo E, Muresanu D, Moessler H. A 24- week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur J Neurol. 2006 Jan 1;13(1):43-54.
Andersen K, Launer JJ, Ott A, et al. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam study. Neurology 1995;45:1441-1445.
Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004 May;61(5):661-6.
Asai M, Hattori C, Iwata N, Saido TC, Sasagawa N, Szabó B, Hashimoto Y, Maruyama K, Tanuma SI, Kiso Y, Ishiura S. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem. 2005 Dec 8.
Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC, Plymate SR. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer’s disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology. 1999 Aug;24(6):657-77.
Atamna H, Frey WH. A role for heme in Alzheimer’s disease: Heme binds amyloid {beta} and has altered metabolism. Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11153-8.
Bae CY, Cho CY, Cho K, Hoon Oh B, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi GD, Cho H, Lee H. A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s disease. J Am Geriatr Soc. 2000 Dec 1;48(12):1566-71.
Baldereschi M, Di Carlo A, Lepore V, Bracco L, Maggi S, Grigoletto F, Scarlato G, Amaducci L. Estrogen-replacement therapy and Alzheimer’s disease in the Italian Longitudinal Study on Aging. Neurology. 1998 Apr;50(4):996-1002.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000 Aug;6(8):916-9.
Bazan NG, Scott BL. Dietary omega-3 fatty acids and accumulation of docosahexaenoic acid in rod photoreceptor cells of the retina and at synapses. Ups J Med Sci Suppl. 1990;48:97-107.
Bazan NG. Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors. Trends Neurosci. 2006 May;29:263–71.
Birge SJ. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? JAGS 1996;44:865-870.
Birks, J.; Flicker, L. Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev 2003;1:CD000442.
Blasko I, Apochal A, Boeck G, Hartmann T, Grubeck-Loebenstein B, Ransmayr G. Ibuprofen decreases cytokine- induced amyloid beta production in neuronal cells. Neurobiol Dis. 2001 Dec;8(6):1094-101.
Bonde C, Noraberg J, Noer H, Zimmer J. Ionotropic glutamate receptors and glutamate transporters are involved in necrotic neuronal cell death induced by oxygen-glucose deprivation of hippocampal slice cultures. Neuroscience. 2005;136(3):779-94.
Boston PF, Bennett A, Horrobin DF, Bennett CN. Ethyl-EPA in Alzheimer’s disease: a pilot study. Prostaglandins Leukot Essent Fatty Acids. 2004 Nov;71:341-346.
Bowen RL, Isley JP, Atkinson RL. An association of elevated serum gonadotropin concentrations and Alzheimer disease? J Neuroendocrinol. 2000 Apr;12(4):351-4.
Bowen RL, Smith MA, Harris PL, Kubat Z, Martins RN, Castellani RJ, Perry G, Atwood CS. Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer’s disease pathology. J Neurosci Res. 2002 Nov 1;70(3):514-8.
Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem. 2004 May 7;279(19):20539-45.
Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population based case-control study. Am J Epidemiol 1994;140:262-267.
Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol. 2005 May;57(5):695- 703.
Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin. 2005 Aug;21(8):1317-27.
Burke WJ, Roccaforte WH, Wengel SP, et al. L-Deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. JAGS 1993;41:1219-1225.
Bush AI, Multhaup G, Moir RD, Williamson TG, Small DH, Rumble B, Pollwein P, Beyreuther K, Masters CL. A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer’s disease. J Biol Chem. 1993 Aug 5;268(22):16109-12.
Bush AI, Pettingell WH, Multhaup G, Paradis Md, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science. 1994 Sep 2;265(5177):1464-7.
Callahan MJ. Combining tacrine with milameline reverses a scopolamine-induced impairment of continuous performance in rhesus monkeys. Psychopharmacology (Berl). 1999 Jun;144 (3):234-8.
Casadesus G, Zhu X, Atwood CS, Webber KM, Perry G, Bowen RL, Smith MA. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer’s disease. Curr Drug Targets CNS Neurol Disord. 2004 Aug;3(4):281-5.
Cerebrolysin in the treatment of dementia. Wien Med Wochenschr. 1997;147(18):426-31.
Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids. 2006 Oct-Nov;75(4-5):259-69.
Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta- amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron. 2001 Jun;30(3):665-76.
Coti Bertrand P, O’Kusky J, Innis SM. Maternal dietary n-3 fatty acid deficiency alters neurogenesis in the embryonic rat brain. J Nutr. 2006 Jun;136(6):1570-5.
Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci. 2001 Jun 15;187(1-2):81-9.
Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficts of Alzheimer’s disease. Neurol 1998;50:1214-1221.
Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26.
Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Des. 2002;8(10):835-43.
Das UN. Estrogen, statins, and polyunsaturated fatty acids: similarities in their actions and benefits-is there a common link? Nutrition. 2002 Feb;18(2):178-88
Davis LL, Ryan W, Adinoff B, Petty F. Comprehensive review of the psychiatric uses of valproate. J Clin Psychopharmacol. 2000 Feb;20(1 Suppl 1):1S-17S.
Delanty N, Vaughan CJ, Sheehy N. Statins and neuroprotection. Expert Opin Investig Drugs. 2001 Oct;10(10):1847-53.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5.
Di Vaira M, Bazzicalupi C, Orioli P, Messori L, Bruni B, Zatta P. Clioquinol, a drug for Alzheimer’s disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem. 2004 Jun 28 ; 43(13):3795-7.
Eriksen JL, Nicolle MM, Prescott S, Ozols VV, Zhuo JM, Smith TE, Beard JL, Weggen S, Sagi SA, Koo EH, Golde TE. Chronic treatment of transgenic APP mice with R- flurbiprofen. 2003 Abstract Viewer/Itinerary Planner, Program No. 295.22. Society for Neuroscience, Washington, DC.
Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest. 2003 Aug 1;112(3):440-9.
Evans, R.M.; Hui, S.; Perkins, A. - Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 2004;62(10):1869-71.
Farías GG, Godoy JA, Vázquez MC, Adani R, Meshulam H, Avila J, Amitai G, Inestrosa NC. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis. 2005 Feb;18(1):176-83.
Fiebich BL, Lieb K, Hull M, Berger M, Bauer J. Effects of NSAIDs on IL-1 beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport. 1996 Apr 26;7(6):1209-13.
Finebrock, A.E.; Bush, A.I.; Doraiswamy, P.M. - Current status of metals as therapeutic targets in Alzheimer’s disease. J Am Geriatr Soc 2003;51(8):1143-8.
Flynn BL, Theesen KA. Pharmacologic management of Alzheimer disease part III: nonsteroidal antiinflammatory drugs-emerging protective evidence? Ann Pharmacother. 1999 Jul-Aug;33(7-8):840-9.
Frampton M, Harvey RJ, Kirchner V. Propentofylline for dementia (cochrane review). Cochrane Database Syst Rev. 2003. CD002853.
Francis-Turner L, Valouskova V. Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study. Neurosci Lett. 1996 Jan 5;202(3):193-6.
Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol. 2006 Oct;63(10):1402-8.
Funke M, Fiehler J, Mewes I, Eiselt M, Rother I, Windisch M. Dose-dependent effects of Cerebrolysin on EEG and short- term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia. J Neural Transm Suppl. 1998;53:385-98.
Gibson GE, Haroutunian V, Zhang H, Park LC, Shi Q, Lesser M, Mohs RC, Sheu RK, Blass JP. Mitochondrial damage in Alzheimer’s disease varies with apolipoprotein E genotype. Ann Neurol. 2000 Sep;48(3):297-303.
Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005 May 10;64(9):1553-62.
Gilman, S.; Koller, M.; Black, R.S. - Neuropsychological, CSF, and neuropathological effects of A-beta immunotherapy (AN1792) of Alzheimer’s disease in an interrupted trial. Neurobiol Aging 2004;25(S2):84.
Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko- Mauro KA, Ellis L, LaFerla FM. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci. 2007 Apr 18;27(16):4385-95.
Green, P.S.; Gridley KE.; Simpkins JW. - Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 1996;218(3):165-8.
Greig NH, De Micheli E, Holloway HW, Yu QS, Utsuki T, Perry TA, Brossi A, Ingram DK, Deutsch J, Lahiri DK, Soncrant TT. The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Suppl. 2000;176:74-84.
Greig NH, Pei XF, Soncrant TT, Ingram DK, Brossi A. Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer’s disease. Med Res Rev. 1995 Jan;15(1):3-31.
Greiner RS, Moriguchi T, Hutton A, Slotnick BM, Salem N Jr. Rats with low levels of brain docosahexaenoic acid show impaired performance in olfactory-based and spatial learning tasks. Lipids. 1999;34 Suppl:S239-43.
Grossfield A, Feller SE, Pitman MC. A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc Natl Acad Sci USA. 2006 Mar 28;103(13):4888-93.
Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002 Jul;57(7):M414-8.
Hao Y, Creson T, Zhang L, Li P, Du F, Yuan P, Gould TD, Manji HK, Chen G. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci. 2004 Jul 21;24(29):6590-9.
Haroutunian V, Greig N, Pei XF, Utsuki T, Gluck R, Acevedo LD, Davis KL, Wallace WC. Pharmacological modulation of Alzheimer’s beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Brain Res Mol. Brain Res. 1997 Jun;46(1-2):161-8.
Hartmann T. Cholesterol, A beta and Alzheimer’s disease. Trends Neurosci. 2001 Nov;24(11 Suppl):S45-8.
Henderson VW, Paganini-Hill A, Miller BL - Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54(2):295-301.
Henderson VW, Paganini-Hill A, Miller BL, Elble RJ, Reyes PF, Shoupe D, McCleary CA, Klein RA, Hake AM, Farlow MR. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology. 2000 Jan 25;54(2):295-301.
Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 2004 May;18(7):902-4.
Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M,
Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of beta-amyloid(1- 40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol. 2004 Mar;61(3):333-7.
Houghton AK, Parsons CG, Headley PM. Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. Pain. 2001 Apr;91(3):201- 7.
Huang, T.H.; Yang, D.S.; Fraser, P.E.; Chakrabartty, A. - Alternate aggregation pathways of the Alzheimer beta-amyloid peptide. An in vitro model of preamyloid. J Biol Chem 2000;275(46):36436-40.
Iijima S, Greig NH, Garofalo P, Spangler EL, Heller B, Brossi A, Ingram DK. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze. Psychopharmacology (Berl). 1993;112(4):415-20.
Ikari H, Spangler EL, Greig NH, Pei XF, Brossi A, Speer D, Patel N, Ingram DK. Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase. Neuroreport. 1995 Feb 15;6(3):481-4.
Imbimbo BP. The potential role of non-steroidal anti- inflammatory drugs in treating Alzheimer’s disease. Expert Opin Investig Drugs. 2004 Nov;13(11):1469-81.
In’t Veld, B.A.; Launer, L.J.; Hoes, A.W. . - NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging 1998;19(6):607-11.
In’t Veld, B.A.; Ruitenberg, A.; Hofman, A.; Launer, L.J.; Van Duijn, C.M.; Stijnen, T.; Breteler M.M.; Stricker, B.H. - Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001;345:1515-21.
Jacoby R. Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer’s disease. Evid Based Ment Health. 2003 Nov;6(4):110.
Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, Coppola D,
Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashec K, Frautschy SA, Cole GM. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001 Nov-Dec;22(6):983-91.
Janus, C.; Pearson, J.; McLaurin, J. - A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 2000;408(6815):979-82.
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000 Nov 11;356 (9242):1627-31.
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000 Nov 11;356 (9242):1627-31. Erratum in: Lancet 2001 Feb 17;357(9255):562.
Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med. 1998 Apr;4(4):447-51.
Kawakita E, Hashimoto M, Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience. 2006;139:991–7.
Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheime’s disease: the Baltimore Longitudinal Study of Aging. Neurol 1997;48:1517-1521.
Kim AJ, Shi Y, Austin RC, Werstuck GH. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J Cell Sci. 2005 Jan 1;118(Pt 1):89-99.
Kitajka K, Puskas LG, Zvara A, Hackler L, Jr., Barcelo- Coblijn G, Farkas ST. The role of n-3 fatty polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci USA. 2002 Mar 5;99(5):2619-24.
Kunik ME, Puryear L, Orengo CA, Molinari V, Workman RH Jr. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry. 1998 Jan;13(1):29-34.
Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH. Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer’s disease. Acta Neurol Scand Suppl. 2000;176:60-7.
Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC, Palumbo PJ. Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol. 1997 Feb 15;145(4):301-8.
Li, G.; Higdon, R.; Kukul, W.A. - Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004;63(9):1624-8. 
Li, S.; Mallory, M.; Alford, M.  - Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 1997;56(8):901-11.
Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci. 2000 Aug 1;20(15):5709-14.
Lim SY, Hoshiba J, Moriguchi T, Salem N Jr. N-3 fatty acid deficiency induced by a modified artificial rearing method leads to poorer performance in spatial learning tasks. Pediatr Res. 2005 Oct;58(4):741-8.
Lindberg C, Crisby M, Winblad B, Schultzberg M. Effects of statins on microglia. J Neurosci Res. 2005 Oct 1;82(1):10- 9.
Lim, G.P.; Yang, F.; Chu, T. - Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 2001;22(6):983-91.
Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry. 2000 Feb;61(2):123-8.
Lingler JH, Martire LM, Schulz R. Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc. 2005 Jun;53(6):983-90.
Lleó A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, Frosch MP, Irizarry M, Hyman BT. Nonsteroidal anti- inflammatory drugs lower Abeta(42) and change presenilin 1 conformation. Nat Med. 2004 Oct;10(10):1065-6.
Lombardi VR, Windisch M, Garcia M, Cacabelos R. Effects of Cerebrolysin on in vitro primary microglial and astrocyte rat cell cultures. Methods Find Exp Clin Pharmacol. 1999 Jun;21(5):331-8.
Loy R, Tariot PN. Neuroprotective properties of valproate: potential benefit for AD and tauopathies. J Mol Neurosci. 2002 Dec;19(3):303-7.
Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, Reback E, Porter V, Swerdloff R, Cummings JL. Effects of Testosterone on Cognition and Mood in Male Patients With Mild Alzheimer Disease and Healthy Elderly Men. Arch Neurol. 2005 Dec 12.
Luo, Y. - Ginkgo biloba neuroprotection: therapeutic implications in Alzheimer’s disease. J Alzheimer’s Dis 2001;3(4):401-7.
Luo. Y.; Smith. J;V.; Paramasivam - Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002;99(19):12197-202.
Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M, Mayeux R. Endogenous estrogen levels and Alzheimer’s disease among postmenopausal women. Neurology. 2000 Feb 22;54(4):833-7.
Mark RJ, Ashford JW, Goodman Y, Mattson MP. Anticonvulsants attenuate amyloid beta-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging. 1995 Mar-Apr;16(2):187-98.
Marks SJ, Batra RR, Frishman WH. Estrogen replacement therapy for cognitive benefits: viable treatment or forgettable ‘senior moment’? Heart Dis. 2002 Jan-Feb;4 (1):26-32.
Marz W, Wollschlager H, Klein G, Neiss A, Wehling M. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol. 1999 Jul 1;84(1):7-13.
Masliah E, Armasolo F, Veinbergs I, Mallory M, Samuel W. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav. 1999 Feb;62(2):239-45.
Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol. 1993 Oct-Dec;6(4):205-9.
McBee WL, Dailey ME, Dugan E, Shumaker SA. Hormone replacement therapy and other potential treatments for dementias. Endocrinol Metab Clin North Am 1997;26:329-45.
McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 1991;337:1304-8.
M’Harzi M, Palou AM, Oberlander C, Barzaghi F. Antagonism of scopolamine-induced memory impairments in rats by the muscarinic agonist RU 35,926 (CI-979). Pharmacol Biochem Behav. 1995 May;51(1):119-24.
Maddalena A, Papassotiropoulos A, Nitsch RM. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron. 2003 May 22;38(4):547-54.
Miller MM, Monjan AA, Buckholtz NS. Estrogen replacement therapy for the potential treatment or prevention of Alzheimer’s disease. Ann N Y Acad Sci. 2001 Dec;949:223- 34.
Misztal, M.; Frankiewicz, T.; Parsons, C.G. et al. - Learning deficits induced by chronic intraventricular infusion of quinolinic acid—protection by MK-801 and memantine. Eur J Pharmacol 1996;296(1):1-8.
Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999 Nov;128(6):1121-32.
Mix, J.A.; Crews, W.D JR. - A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 2002;17(6):267-77.
Molloy DW, Standish TI. Clinical experience with Cerebrolysin. J Neural Transm Suppl. 2000;59:293-300.
Monsego, A.; Zota, V.; Karni, A.  - Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003;112(3):415-22.
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000 Dec 21-28;408 (6815):982-5. Erratum in: Nature 2001 Aug 9;412(6847):660.
Morgan D, Gordon MN. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002 Mar 15;22(6):2246-54.
Morgan, D.; Diamond, D.M.; Gottschall, P.E.; - A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000;408(6815):982-5.
Moriguchi T, Salem N Jr. Recovery of brain docosahexaenoate leads to recovery of spatial task performance. J Neurochem. 2003 Oct;87(2):297-309.
Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem. 2002 Nov ;83(4):1009-12.
Morris JC, Cyrus PA, Orazem J. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurol 1998;50:1222-1230.
Morse LJ, Payton SM, Cuny GD, Rogers JT. FDA-Preapproved Drugs Targeted to the Translational Regulation and Processing of the Amyloid Precursor Protein. J Mol Neurosci. 2004;24(1):129-36.
Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer’s Disease Cooperative Study. JAMA. 2000 Feb 23;283(8):1007-15.
Multhaup G, Schlicksupp A, Hesse L, Beher D, Ruppert T, Masters CL, Beyreuther K. The amyloid precursor protein of Alzheimer’s disease in the reduction of copper(II) to copper(I). Science. 1996 Mar 8;271(5254):1406-9.
Muresanu DF, Rainer M, Moessler H. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002;277-85.
Nathan L, Chaudhuri G. Antioxidant and prooxidant actions of estrogens: potential physiological and clinical implications. Semin Reprod Endocrinol. 1998;16(4):309-14. Review.
Nicoll, J.A.; Wilkinson, D.; Holmes C. - Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9(4):448-52.
Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. Anti-inflammatory properties of cholinergic up-regulation: A new role for acetylcholinesterase inhibitors. Neuropharmacology. 2005 Dec 2.
Nye JS, Ellerbrock BR, Pauley AM, et al. Modulators of the Gamma Secretase Reciprocally Regulate Short and Long A Peptides and Spare - Site Cleavages. Proceedings of the 9th International Alzheimer’s Disease and Related Disorders, July 17-22, 2004, Philadelphia.
Orgogozo, J.M.; Gilman, S.; Dartigues, J.F. - Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61(1):46-54.
Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 19944;140:256-261.
Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-2217.
Panisset M, Gauthier S, Moessler H, Windisch M. Cerebrolysin in Alzheimer’s disease: a randomized, double- blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm. 2002 Jul;109(7-8):1089-104.
Paris D, Townsend KP, Humphrey J, Obregon DF, Yokota K, Mullan M. Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis. 2002 Apr;161(2):293-9.
Parsons CG, Danysz W, Quack G. Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists--in vitro characterisation. Amino Acids. 2000;19(1):157-66.
Patel N, Spangler EL, Greig NH, Yu QS, Ingram DK, Meyer RC. Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor. Neuroreport. 1998 Jan 5;9(1):171-6.
Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyorala K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1996 Oct 14;156(18):2085- 92.
Pedersen TR, Tobert JA. Simvastatin: a review. Expert Opin Pharmacother. 2004 Dec;5(12):2583-96.
Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol. 2006 Jun;199(2):265-73.
Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002 Nov 15;298(5597):1379.
Pike CJ. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer’s disease. J Neurochem. 1999 Apr;72(4):1552-63.
Pitchumoni SS, Doraiswamy PM. Current status of antioxidant therapy for Alzheimer’s disease. JAGS 1998;46:1566-1572.
Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L, Noviasky J, Kowalski N, Holt CJ, Irvine C. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry. 2001 Winter;9(1):58-66.
Prelevic GM, Jacobs HS. New developments in postmenopausal hormone replacement therapy. Curr Opin Obstet Gynecol 1997 Jun;9(3):207-12.
Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl- cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non- competitive manner. Neurosci Lett. 2001 Jun 22;306(1-2):81- 4.
Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Xilinas M, Gottfries CG. Treatment of Alzheimer’s disease with clioquinol. Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):408-14.
Resnick SM, Maki PM. Effects of hormone replacement therapy on cognitive and brain aging. Ann N Y Acad Sci. 2001 Dec;949:203-14.
Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology. 1995 Jan;45(1):51-5.
Rigney, U.; Kimber, S.; Hindmarch, I. - The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res 1999;13(5):408-15.
Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD; Rosiglitazone in Alzheimer’s Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54.
Rosenberg RN. Metal chelation therapy for Alzheimer disease. Arch Neurol. 2003 Dec;60(12):1678-9.
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny RA, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003 Dec;60(12):1685-91.
Ritchie CW, Bush AI, Masters CL. Metal-protein attenuating compounds and Alzheimer’s disease. Expert Opin Investig Drugs. 2004 Dec ;13(12):1585-92.
Ritchie, C.W.; Bush, A.I.; Mackinnon - Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60(12):1685-91.
Rockenstein E, Adame A, Mante M, Larrea G, Crews L, Windisch M, Moessler H, Masliah E. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound cerebrolysin. J Neural Transm. 2005 Feb 1;112(2):269-82.
Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E. The neuroprotective effects of Cerebrolysin trade mark in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance. J Neural Transm. 2003 Nov;110(11):1313-27.
Rockenstein E, Torrance M, Mante M, Adame A, Paulino A, Rose JB, Crews L, Moessler H, Masliah E. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer’s disease. J Neurosci Res. 2006 May 15;83 (7):1252-61.
Rogers J, Kirby LC, Hempelman SR,. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993;43:1609-1611.
Ruether E, Alvarez XA, Rainer M, Moessler H. Sustained improvement of cognition and global function in patients with moderately severe Alzheimer’s disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin. J Neural Transm Suppl. 2002;265-75.
Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, Ritter R, Schmidt R, Taneri Z, Winterer W, Koper D, Kasper S, Rainer M, Moessler H. A 28-week, double- blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Int Clin Psychopharmacol. 2001 Sep;16(5):253-63.
Ruther E, Ritter R, Apecechea M, Freytag S, Gmeinbauer R, Windisch M. Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapy. J Neural Transm. 2000;107(7):815-29.
Salem N, Jr., Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic aicd in the nervous system. Lipids. 2001 Sep;36:945–59.
Sano M, Ernesto C, Thomas RG. A controlled trial of selegiline, alpha-tocopherol, or both as treatment of Alzheimer’s disease. NEJM 1997;336:1216-1222.
Sastre, J, Pallardo, F.V., Vina, J. - Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000;49(5):427-35.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J,Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999 Jul 8;400(6740):173-7.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J,Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Schwarz RD, Callahan MJ, Coughenour LL, Dickerson MR, Kinsora JJ, Lipinski WJ, Raby CA, Spencer CJ, Tecle H. Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J Pharmacol Exp Ther. 1999 Nov;291(2):812-22.
Schwab M, Schaller R, Bauer R, Zwiener U. Morphofunctional effects of moderate forebrain ischemia combined with short- term hypoxia in rats protective effects of Cerebrolysin. Exp Toxicol Pathol. 1997 Feb;49(1-2):29-37.
Scott HD, Laake K. Statins for the reduction of risk of Alzheimer’s disease. Cochrane Database Syst Rev. 2001;(3):CD003160.
Sedman AJ, Bockbrader H, Schwarz RD. Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer’s disease. Life Sci. 1995;56(11-12):877-82.
Shanks MF, Venneri A. Conventional trial designs offer limited clinical understanding of cholinesterase-inhibitor treatment effects in Alzheimer disease. Am J Geriatr Psychiatry. 2005 Feb ;13(2):170; author reply 170-1.
Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A. 2001 Jun 19;98 (13):7605-10.
Short RA, Bowen RL, O’Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001 Sep;76(9):906-9.
Short RA, Bowen RL, O’Brien PC, Graff-Radford NR. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin Proc. 2001 Sep;76(9):906-9.
Shumaker SA.; Legault C.; Rapp SR.;  - Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289(20):2651-62.
Shumaker, S.A.; Legault, C.; Kuller, L. - Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 2004;291(24):2947-58.
Siemers, E.; Dean, R.A.; Satterwhite J.; - Safety, tolerability, and changes in plasma and cerebrospinal fluid amyloid beta concentrations after administration of a functional gamma-secretase inhibitor in healthy volunteers. Neurobiol Aging 2004;25(S2):569.
Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002 Sep;52(3):346-50.
Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K. Treatment with simvastatin in patients with Alzheimer’s disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord. 2003;16(1):25-30.
Skoog I, Gustafson D. HRT and dementia. J Epidemiol Biostat. 1999;4(3):227-51;discussion 252.
Slooter AJ, Bronzova J, Witteman JC, Van Broeckhoven C, Hofman A, van Duijn CM. Estrogen use and early onset Alzheimer’s disease: a population-based study. J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):779-81.
Sramek JJ, Sedman AJ, Reece PA, Hourani J, Bockbrader H, Cutler NR. Safety and tolerability of CI-979 in patients with Alzheimer’s disease. Life Sci. 1995;57(5):503-10.
Stewart WF, Kawas C, Corrada M, Metter EJ.  Risk of Alzheimer’s disease and duration of NSAID use. Neurol 1997;48:626-632.
Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev. 2005 Sep-Oct;45(5):559-79.
Stratman NC, Carter DB, Sethy VH. Ibuprofen: effect on inducible nitric oxide synthase. Brain Res Mol Brain Res. 1997 Oct 15;50(1-2):107-12.
Tabet, N.; Feldmand, H. - Ibuprofen for Alzheimer’s disease. Cochrane Database Syst Rev 2003;2:CD004031.
Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet. 1996 Aug 17;348(9025):429-32.
Tatebayashi Y, Lee MH, Li L, Iqbal K, Grundke-Iqbal I. The dentate gyrus neurogenesis: a therapeutic target for Alzheimer’s disease. Acta Neuropathol (Berl). 2003 Mar;105 (3):225-32.
Tennant FS. Preliminary observations on naltrexone for treatment of Alzheimer’s type dementia. J Am Geriatrics Soc 1987;35:369-70.
Thal LJ, Fuld PA. Memory enhancement with oral physostigmine in Alzheimer’s disease. New Engl J Med 1983;308:720.
Thomas T, Rhodin JA, Sutton ET, Bryant MW, Price JM. Estrogen protects peripheral and cerebral blood vessels from toxicity of Alzheimer peptide amyloid-beta and inflammatory reaction. J Submicrosc Cytol Pathol. 1999 Oct;31(4):571-9.
Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA, Multhaup G. Clioquinol Mediates Copper Uptake and Counteracts Copper Efflux Activities of the Amyloid Precursor Protein of Alzheimer’s Disease. J Biol Chem. 2004 Dec 10; 279(50):51958-51964.
Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ. Low serum cholesteryl ester- docosahexaenoic acid levels in Alzheimer’s disease: a case- control study. Br J Nutr. 2003 Apr;89(4):483-9.
Veinbergs I, Mante M, Mallory M, Masliah E. Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity. J Neural Transm Suppl. 2000;59:273-80.
Vreugdenhil M, Bruehl C, Voskuyl RA, Kang JX, Leaf A, Wadman WJ. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci USA. 1996 Oct 29;93(22):12559-63.
Wang R, Tang XC. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer’s disease. Neurosignals. 2005;14(1-2):71-82.
Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs. 2003;17(1):27-45.
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem. 2003 Aug 15;278 (33):30748-54.
Wilcock GK, Black S, Haworth J, Laughlin M, Hendrix S, Binger M, Zavitz K, Swabb E, Hobden A. A Placebo- controlled, Double-blind Trial of the Selective Aâ-42 Lowering Agent, Flurizan (MPC-7869, (R)-flurbiprofen) in Patients with Mild to Moderate Alzheimer’s Disease. Alzheimer’s Association International Conference on Prevention of Dementia, June 18-21, 2005 , Washington DC.
Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, Golde TE, Koo EH. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem. 2003 Aug 22;278(34):31831-7.
White, A.R.; Hawke, S.H. - Immunotherapy as a therapeutic treatment for neurodegenerative disorders. J Neurochem 2003;87:801-8.
Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000 Oct;57(10):1439-43.
Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P, Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med. 1998 Apr;4(4):447-51.
Yednock T, Games D, Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999 Jul 8;400(6740):173-7.
Yu Q, Holloway HW, Flippen-Anderson JL, Hoffman B, Brossi A, Greig NH. Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem. 2001 Nov 22;44(24):4062-71.
Zheng XM. Detecting Regional Cerebral Blood Flow Changes in Alzheimer’s Patients After Milameline Treatment: Activation or Baseline SPECT? J Nucl Med Technol. 2002 Sep;30(3):118-22.
Zhou, L.J.; Zhu, X.Z. - Reactive oxygen species-induced apoptosis in PC12 cells and protective effect of bilobalide. J Pharmacol Exp Ther, 2000;293(3):982-

 

 

Veja também:

Antagonista dos Receptores de Glutamato

Bases Atuais da Terapêutica

Inibidores da Acetilcolinesterase (Parte 1)

Inibidores da Acetilcolinesterase (Parte 2)

Novas Drogas - Perspectivas (Parte 1)

Novas Drogas - Perspectivas (Parte 2)

Outras Possibilidades Terapêuticas

Tratamento não Farmacológico

Tratamento Sintomático